LU92200I1 - Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables - Google Patents
Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptablesInfo
- Publication number
- LU92200I1 LU92200I1 LU92200C LU92200C LU92200I1 LU 92200 I1 LU92200 I1 LU 92200I1 LU 92200 C LU92200 C LU 92200C LU 92200 C LU92200 C LU 92200C LU 92200 I1 LU92200 I1 LU 92200I1
- Authority
- LU
- Luxembourg
- Prior art keywords
- linaclotide
- protected
- pharmaceutically acceptable
- acceptable salts
- including pharmaceutically
- Prior art date
Links
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 title 1
- 229960000812 linaclotide Drugs 0.000 title 1
- 108010024409 linaclotide Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44309803P | 2003-01-28 | 2003-01-28 | |
| US47128803P | 2003-05-15 | 2003-05-15 | |
| US51946003P | 2003-11-12 | 2003-11-12 | |
| PCT/US2004/002390 WO2004069165A2 (fr) | 2003-01-28 | 2004-01-28 | Procedes et compositions pour le traitement de troubles gastro-intestinaux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LU92200I1 true LU92200I1 (fr) | 2020-06-02 |
| LU92200I2 LU92200I2 (fr) | 2024-03-21 |
Family
ID=32854294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92200C LU92200I2 (fr) | 2003-01-28 | 2013-05-22 | Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables |
| LU92201C LU92201I2 (fr) | 2003-01-28 | 2013-05-22 | Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92201C LU92201I2 (fr) | 2003-01-28 | 2013-05-22 | Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20040266989A1 (fr) |
| EP (3) | EP1594517B1 (fr) |
| JP (3) | JP4584911B2 (fr) |
| KR (2) | KR101227627B1 (fr) |
| CN (2) | CN101787073B (fr) |
| AT (2) | ATE365174T1 (fr) |
| AU (2) | AU2004210161B2 (fr) |
| BE (1) | BE2013C032I2 (fr) |
| BR (2) | BRPI0407071B8 (fr) |
| CA (1) | CA2514507C (fr) |
| CY (5) | CY1110905T1 (fr) |
| DE (2) | DE602004028678D1 (fr) |
| DK (3) | DK2246360T3 (fr) |
| ES (3) | ES2387848T3 (fr) |
| FR (2) | FR13C0029I2 (fr) |
| HK (1) | HK1078768A1 (fr) |
| HU (1) | HUS1300022I1 (fr) |
| IL (2) | IL169863A (fr) |
| LT (1) | LTC1594517I2 (fr) |
| LU (2) | LU92200I2 (fr) |
| MX (1) | MXPA05008097A (fr) |
| NL (1) | NL300593I2 (fr) |
| NO (3) | NO334112B1 (fr) |
| NZ (2) | NZ541595A (fr) |
| PT (3) | PT1594517E (fr) |
| RU (2) | RU2543350C2 (fr) |
| SG (2) | SG192300A1 (fr) |
| SI (3) | SI2246360T1 (fr) |
| WO (1) | WO2004069165A2 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2944648B1 (fr) | 2001-03-29 | 2019-11-13 | Bausch Health Ireland Limited | Agonistes du récepteur du type Guanylate Cyclase servant au traitement de l'inflammation d'organe |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20060281682A1 (en) * | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| RU2543350C2 (ru) * | 2003-01-28 | 2015-02-27 | Айронвуд Фармасьютикалз, Инк. | Способы и композиции для лечения желудочно-кишечных расстройств |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2526958B1 (fr) * | 2003-06-13 | 2017-10-18 | Ironwood Pharmaceuticals, Inc. | Procédé et compositions de traitement des troubles gastro-intestinaux |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| US20050266028A1 (en) * | 2004-05-25 | 2005-12-01 | University Of Georgia Research Foundation, Inc. | Compositions and methods for modulating an immune response |
| JPWO2006046746A1 (ja) * | 2004-10-26 | 2008-05-22 | 味の素株式会社 | 内臓痛予防・治療剤 |
| EP1940441A4 (fr) * | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | Compositions et methodes de traitement de troubles gastro-intestinaux |
| PL1937262T3 (pl) | 2005-09-29 | 2019-10-31 | Ipsen Pharma | Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego |
| CA2652677A1 (fr) * | 2006-02-24 | 2007-09-07 | Ironwood Pharmaceuticals, Inc. | Methodes et compositions servant au traitement de troubles gastro-intestinaux |
| EP2129683A4 (fr) * | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | Procedes et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles |
| EP2671584A3 (fr) * | 2007-05-04 | 2014-03-26 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter des troubles associés à la rétention de sel ou de fluide |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| EP2810951B1 (fr) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
| EP2296685B1 (fr) | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
| US20110306125A1 (en) * | 2008-06-30 | 2011-12-15 | Ironwood Pharmaceuticals, Inc. | Protein Expression Methods |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| BRPI0917807A2 (pt) * | 2008-08-15 | 2019-11-19 | Forest Laboratories Holdings Ltd | formulação sólida estável de um polipeptídeo agonista de recepto gc-c adequada para administração oral |
| EP2365821A4 (fr) | 2008-11-19 | 2013-09-04 | Ironwood Pharmaceuticals Inc | Forme cristalline de la linaclotide |
| ES2608050T3 (es) * | 2008-12-03 | 2017-04-05 | Synergy Pharmaceuticals Inc. | Formulaciones de agonistas de guanilato ciclasa C y métodos de uso |
| DK2417152T3 (da) | 2009-04-10 | 2013-12-16 | Corden Pharma Colorado Inc | Fremgangsmåde til isolering af linaclotid |
| CA2770077A1 (fr) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprenant du linaclotide |
| EP2464373A1 (fr) * | 2009-08-13 | 2012-06-20 | Ironwood Pharmaceuticals, Inc. | Procédé de modulation de l'effet pharmacodynamique d'agonistes des récepteurs de guanylate cyclase administrés par voie orale |
| JP5913115B2 (ja) | 2009-11-09 | 2016-05-11 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 胃腸障害のための処置 |
| US8735360B2 (en) | 2009-12-07 | 2014-05-27 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| PL2536742T3 (pl) | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
| WO2011145062A1 (fr) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Traitement des acouphènes et de dysfonctions auditives apparentées |
| EP2605786A4 (fr) * | 2010-06-09 | 2014-03-12 | Combimab Inc | Peptides thérapeutiques |
| JP5921545B2 (ja) | 2010-08-11 | 2016-05-24 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | リナクロチドの安定な製剤 |
| WO2012037380A2 (fr) | 2010-09-15 | 2012-03-22 | Synergy Pharmaceuticals Inc. | Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9650417B2 (en) | 2011-05-11 | 2017-05-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012155114A1 (fr) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux |
| US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
| MD480Z5 (ro) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Metodă de tratament al colitei ulceroase nespecifice acute |
| CN104053449B (zh) | 2011-08-17 | 2016-12-07 | 硬木药品公司 | 胃肠疾患的治疗 |
| EA022546B1 (ru) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Способ торможения роста карциномы эрлиха у лабораторного животного |
| JP2016521249A (ja) * | 2012-07-12 | 2016-07-21 | フォレスト ラボラトリーズ ホールディングス リミテッド | リナクロチド組成物 |
| RU2528641C2 (ru) * | 2012-08-22 | 2014-09-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела |
| CN102875655B (zh) * | 2012-09-29 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种合成利那洛肽的方法 |
| WO2014118180A1 (fr) | 2013-01-30 | 2014-08-07 | Sandoz Ag | Forme cristalline de linaclotide |
| CA2905438A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
| AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP6930919B2 (ja) * | 2015-05-01 | 2021-09-01 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 結腸洗浄及び胃腸障害の治療のための組成物 |
| WO2017160938A1 (fr) * | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine α8β1 |
| CN107929718A (zh) * | 2017-10-19 | 2018-04-20 | 南京星银药业集团有限公司 | Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法 |
| CN113260407B (zh) * | 2018-10-23 | 2023-11-14 | 艾比科生物医学公司 | 输送装置 |
| CN109467606A (zh) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 |
| WO2020237096A1 (fr) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combinaison pour baisser le phosphate sérique chez un patient |
| RU2712761C1 (ru) * | 2019-07-02 | 2020-01-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких |
| CN111265653B (zh) * | 2020-02-09 | 2023-05-09 | 华中科技大学同济医学院附属协和医院 | 心房利钠肽在制备炎症性肠病治疗药物中的应用 |
| WO2021191865A1 (fr) * | 2020-03-26 | 2021-09-30 | Dusa Pharmaceuticals, Inc. | Gestion de lésions de la neurofibromatose dermique |
| WO2023144292A1 (fr) | 2022-01-28 | 2023-08-03 | Fresenius Kabi Ipsum S.R.L. | Procédé de préparation de linaclotide |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US266989A (en) * | 1882-11-07 | Automatic fire | ||
| US152868A (en) * | 1874-07-07 | Improvement in type-setting machines | ||
| US73628A (en) * | 1868-01-21 | mitchell | ||
| US232013A (en) * | 1880-09-07 | Henry h | ||
| US258687A (en) * | 1882-05-30 | Grain-binder | ||
| US32684A (en) * | 1861-07-02 | Stump-extkactob | ||
| US121961A (en) * | 1871-12-19 | Improvement in devices for supporting pipe-cores | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US6342373B1 (en) * | 1983-11-21 | 2002-01-29 | Ucp Gen-Pharma Ag | Process for preparing recombinant eglin, protease inhibitor |
| IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| CH679207A5 (fr) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| CA2046830C (fr) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5140102A (en) * | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
| RU2194760C2 (ru) * | 1991-12-02 | 2002-12-20 | Кор Терапьютикс, Инк. | Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида |
| US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
| SG50624A1 (en) | 1991-12-30 | 1998-07-20 | Neurex Corp | Methods of producing analgesia and enhancing opiate analgesia |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5969097A (en) | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
| CA2150574A1 (fr) | 1993-01-06 | 1994-07-21 | Shalaby W. Shalaby | Conjugues moleculaires ioniques de polyesters degradables et de polypeptides bioactifs |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5395490A (en) | 1993-05-14 | 1995-03-07 | Intertec, Ltd. | Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies |
| US6060037A (en) * | 1993-10-26 | 2000-05-09 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
| US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
| EP1336409B1 (fr) | 1995-06-27 | 2007-04-11 | Eisai R&D Management Co., Ltd. | Compositions et formulations permettant de produire une analgésie et d'inhiber la progression de troubles liés à des douleurs neuropathiques |
| US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
| KR19990071597A (ko) | 1995-11-24 | 1999-09-27 | 파올로 비지, 엔리꼬 카쭐라니 | 퀴놀린 유도체 |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| EP0895517B1 (fr) | 1996-04-23 | 2004-11-17 | Ipsen Manufacturing Ireland Limited | Polymeres polylactiques acides |
| US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| ATE386531T1 (de) | 1997-02-28 | 2008-03-15 | Nycomed Gmbh | Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse- agonisten |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
| WO1999014239A1 (fr) | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Composition pour le traitement du diabete sucre et de l'obesite |
| US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| DK1185294T3 (da) | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
| HUP0203060A3 (en) | 1999-08-18 | 2003-11-28 | Sod Conseils Rech Applic | Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same |
| SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
| AU7700400A (en) | 1999-10-06 | 2001-05-10 | Pharmacia Corporation | Uroguanylin as an intestinal cancer inhibiting agent |
| EP1225897B1 (fr) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition destinee au traitement de la constipation et du syndrome du colon irritable |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| WO2001064212A1 (fr) | 2000-03-01 | 2001-09-07 | University College London | Modulateurs de l'absorption d'endocannabinoide et des recepteurs de vallinoide |
| PT1216707E (pt) | 2000-12-22 | 2005-06-30 | Pasteur Institut | Novas utilizacoes terapeuticas para um smr-1-peptideo |
| WO2002062369A2 (fr) | 2001-02-02 | 2002-08-15 | Pharmacia Corporation | Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin |
| EP2944648B1 (fr) | 2001-03-29 | 2019-11-13 | Bausch Health Ireland Limited | Agonistes du récepteur du type Guanylate Cyclase servant au traitement de l'inflammation d'organe |
| WO2002079235A2 (fr) | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere |
| MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
| CA2464511A1 (fr) | 2001-06-05 | 2002-12-12 | Yalcin Cetin | Utilisation d'un peptide qui active la guanylate-cyclase c pour le traitement de maladies des voies respiratoires par les voies aeriennes, medicament, dispositif d'inhalation et methode de diagnostic |
| FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| EP1321142A1 (fr) | 2001-12-21 | 2003-06-25 | Novartis AG | Forme solide pour l'administration orale du Tégaserode |
| US20040121961A1 (en) | 2002-02-04 | 2004-06-24 | Jaime Masferrer | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| AU2003224644A1 (en) | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| CA2479350A1 (fr) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Inhibiteurs de recaptage de 5-ht pour le traitement de syndromes de la douleur viscerale |
| RU2336871C2 (ru) | 2002-05-17 | 2008-10-27 | Тиога Фармасьютиклз, Инк. | Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора |
| US20060281682A1 (en) | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| RU2543350C2 (ru) * | 2003-01-28 | 2015-02-27 | Айронвуд Фармасьютикалз, Инк. | Способы и композиции для лечения желудочно-кишечных расстройств |
| WO2004071436A2 (fr) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | Utilisation de ligands gcc |
| EP1940441A4 (fr) * | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | Compositions et methodes de traitement de troubles gastro-intestinaux |
-
2004
- 2004-01-28 RU RU2008147983/15A patent/RU2543350C2/ru active
- 2004-01-28 EP EP04706011A patent/EP1594517B1/fr not_active Expired - Lifetime
- 2004-01-28 AU AU2004210161A patent/AU2004210161B2/en active Active
- 2004-01-28 ES ES10170038T patent/ES2387848T3/es not_active Expired - Lifetime
- 2004-01-28 DK DK10170038.3T patent/DK2246360T3/da active
- 2004-01-28 PT PT04706011T patent/PT1594517E/pt unknown
- 2004-01-28 ES ES07011869T patent/ES2350123T3/es not_active Expired - Lifetime
- 2004-01-28 BR BRPI0407071A patent/BRPI0407071B8/pt active IP Right Grant
- 2004-01-28 CN CN2009102662250A patent/CN101787073B/zh not_active Expired - Lifetime
- 2004-01-28 SG SG2012003802A patent/SG192300A1/en unknown
- 2004-01-28 DE DE602004028678T patent/DE602004028678D1/de not_active Expired - Lifetime
- 2004-01-28 SG SG200705302-8A patent/SG168407A1/en unknown
- 2004-01-28 BR BR122018074353A patent/BR122018074353B8/pt active IP Right Grant
- 2004-01-28 ES ES04706011T patent/ES2285417T3/es not_active Expired - Lifetime
- 2004-01-28 DK DK07011869.0T patent/DK1911763T3/da active
- 2004-01-28 PT PT07011869T patent/PT1911763E/pt unknown
- 2004-01-28 EP EP07011869A patent/EP1911763B1/fr not_active Expired - Lifetime
- 2004-01-28 DE DE602004007105T patent/DE602004007105T2/de not_active Expired - Lifetime
- 2004-01-28 DK DK04706011T patent/DK1594517T3/da active
- 2004-01-28 KR KR1020117019764A patent/KR101227627B1/ko active IP Right Grant
- 2004-01-28 EP EP10170038A patent/EP2246360B1/fr not_active Expired - Lifetime
- 2004-01-28 CN CN200480008533A patent/CN100589839C/zh not_active Expired - Lifetime
- 2004-01-28 NZ NZ541595A patent/NZ541595A/en not_active IP Right Cessation
- 2004-01-28 NZ NZ570134A patent/NZ570134A/en not_active IP Right Cessation
- 2004-01-28 US US10/766,735 patent/US20040266989A1/en not_active Abandoned
- 2004-01-28 AT AT04706011T patent/ATE365174T1/de active
- 2004-01-28 KR KR1020057013966A patent/KR101227626B1/ko active IP Right Grant
- 2004-01-28 RU RU2005127058/15A patent/RU2353383C2/ru active
- 2004-01-28 PT PT10170038T patent/PT2246360E/pt unknown
- 2004-01-28 MX MXPA05008097A patent/MXPA05008097A/es active IP Right Grant
- 2004-01-28 SI SI200431918T patent/SI2246360T1/sl unknown
- 2004-01-28 AT AT07011869T patent/ATE477268T1/de active
- 2004-01-28 SI SI200430401T patent/SI1594517T1/sl unknown
- 2004-01-28 WO PCT/US2004/002390 patent/WO2004069165A2/fr active Application Filing
- 2004-01-28 SI SI200431521T patent/SI1911763T1/sl unknown
- 2004-01-28 CA CA2514507A patent/CA2514507C/fr not_active Expired - Lifetime
- 2004-01-28 JP JP2006503109A patent/JP4584911B2/ja not_active Expired - Lifetime
-
2005
- 2005-07-25 IL IL169863A patent/IL169863A/en active IP Right Grant
- 2005-08-18 NO NO20053864A patent/NO334112B1/no not_active IP Right Cessation
- 2005-11-23 HK HK05110618A patent/HK1078768A1/xx not_active IP Right Cessation
-
2007
- 2007-08-09 CY CY20071101072T patent/CY1110905T1/el unknown
- 2007-10-31 US US11/930,696 patent/US7704947B2/en not_active Expired - Lifetime
-
2009
- 2009-11-10 AU AU2009235993A patent/AU2009235993B2/en active Active
-
2010
- 2010-04-05 US US12/754,138 patent/US8080526B2/en not_active Expired - Lifetime
- 2010-06-22 JP JP2010141519A patent/JP5563384B2/ja not_active Expired - Lifetime
- 2010-11-04 CY CY20101101000T patent/CY1111058T1/el unknown
-
2012
- 2012-08-09 IL IL221380A patent/IL221380A0/en active IP Right Grant
- 2012-09-19 CY CY20121100859T patent/CY1113217T1/el unknown
-
2013
- 2013-02-28 JP JP2013038602A patent/JP5748791B2/ja not_active Expired - Lifetime
- 2013-04-05 NO NO20130460A patent/NO336768B1/no not_active IP Right Cessation
- 2013-05-22 LU LU92200C patent/LU92200I2/fr unknown
- 2013-05-22 LU LU92201C patent/LU92201I2/fr unknown
- 2013-05-22 LT LTPA2013013C patent/LTC1594517I2/lt unknown
- 2013-05-22 HU HUS1300022 patent/HUS1300022I1/hu unknown
- 2013-05-22 NL NL300593C patent/NL300593I2/nl unknown
- 2013-05-23 FR FR13C0029C patent/FR13C0029I2/fr active Active
- 2013-05-23 FR FR13C0030C patent/FR13C0030I1/fr active Active
- 2013-05-24 CY CY2013022C patent/CY2013022I1/el unknown
- 2013-05-24 CY CY2013021C patent/CY2013021I1/el unknown
- 2013-05-24 BE BE2013C032C patent/BE2013C032I2/nl unknown
-
2014
- 2014-05-21 NO NO2014013C patent/NO2014013I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92200I1 (fr) | Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables | |
| LU92035I2 (fr) | Vemurafenib et les sels pharmaceutiquement acceptables de celui-ci, sous toutes les formes bénéficiant de la protection conférée par le brevet de base | |
| LU91960I2 (fr) | Télaprévir et chaque forme thérapeutiquement équivalente de celui-ci protégéé par le brevet de base,tels que des sels pharmaceutiquement acceptables et/ou solvates de télaprévir ou solvates de tels sels | |
| LU92182I2 (fr) | Dapagliflozine et ses sels pharmaceutiquement acceptables | |
| DK1575618T3 (da) | Dispergerbare farmaceutiske kombinationer | |
| EP1708748A4 (fr) | Immunogene et vaccin contre la grippe | |
| DE60124587D1 (de) | 2-butyl-3-(4-3(dibutylamino)propoxyü benzoyl)-5-nitrobenzofuran-hydrochlorid und dessen herstellung | |
| PT1501534E (pt) | Formulacoes farmaceuticas | |
| NO20033566L (no) | Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler | |
| IS7831A (is) | Bóluefni | |
| NO20025357D0 (no) | Antranylamider og deres anvendelse som legemidler | |
| DK1614687T3 (da) | Fremgangsmåde til fremstilling af 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onderivater og deres anvendelse ved syntese af ivabradin og farmaceutisk acceptable salte deraf | |
| NO20050689L (no) | Terapeutisk anvendelse | |
| PL394604A1 (pl) | Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna | |
| NO20044188L (no) | Kontrollerte frigjoringsdoseformer | |
| NL1024677A1 (nl) | Therapeutische prolinederivaten. | |
| DK1597171T3 (da) | Terapeutisk mikroskum | |
| DE60328408D1 (de) | Impfstoff | |
| NO20051561D0 (no) | Vaksine | |
| DE60232445D1 (de) | Cetirizin und pseudoephedrin enthaltende tablette | |
| DE60226218D1 (de) | Impfstoff gegen pferdeherpesvirus | |
| EG24959A (en) | Indoles useful in the treatment of androgenreceptor related diseases. | |
| DE60125927D1 (de) | Impfstoffe gegen hiv | |
| DE60307688D1 (de) | Hardware-unterstützter Tupelraum | |
| DK1618130T3 (da) | Terapeutisk cancervaccine |